MedTrace Logo

Use of ARINA-1 in an Intermediate Size Patient Population of Bilateral Lung Transplant Patients With CLAD Grade 0

NCT03226431 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2019-07-05

No results posted yet for this study

Summary

To treat an intermediate size patient population of bilateral lung transplant patients with CLAD-0.

Conditions

  • Lung Transplant

Interventions

DRUG

Ascorbic Acid

ARINA-1 (inhaled ascorbic acid 88 mg/ml) will be nebulized twice daily for 3 months using a PARI eFlow nebulizer

Sponsors & Collaborators

Principal Investigators

  • Omar Mohamedaly, MD · Duke Health

  • Lorenzo Zaffiri, MD · Duke Health

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-12-11
Primary Completion
2019-06-25
Completion
2019-06-25
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03226431 on ClinicalTrials.gov